ERBB2 and non-small cell lung carcinoma: For example, a retrospective study reported that the ORR, median progression-free survival (PFS), and overall survival (OS) rates at 1 year were respectively 52%, 6 months, and 88% in 27 patients with advanced NSCLC who carried HER2 mutations and received first-line ICIs in combination with chemotherapy (11).